CSF-tau, CSF-Aβ1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: Combination of CSF-tau and MMSE yields highest sensitivity and specificity

Journal of Neural Transmission

Volumn 110, Issue 10, 2003, Pages 1149-1160

  Ganzer, S ^a   Arlt, S ^a   Schoder, V ^a   Buhmann, C ^a   Mandelkow, E M ^b   Finckh, U ^a   Beisiegel, U ^a   Naber, D ^a   Muller Thomsen T ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Alzheimer disease; Amyloid beta 1 42; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; TAU PROTEIN;

ADOLESCENT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS;

EID: 0142027660     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0017-7     Document Type: Article

References (45)

1. Andreasen N, Blennow K (2002) β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 23: 1205-1214
2. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (1999) Sensitivity, specifity and stability of CSF-tau in AD in a community-based patient sample. Neurology 53: 1488-1494
3. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B (1999) Cerebrospinal fluid β-amyloid 1-42 in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 56: 673-680
4. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K (1999) Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273: 5-8
5. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Aβ1-42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58: 373-379
6. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Matsushita S, Machida N, Nakagawa T, Lee VM, Trojanowski JQ, Sasaki H (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 38: 649-52
7. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 26: 231-245
8. Briani C, Ruggero S, Naccarato M, Cagnin A, Ricchieri L, Pasqui L, Pizzolato G, Battistin L (2002) Combined analysis of CSF Aβ42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. J Neural Transm 109: 393-398
9. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental-State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
10. Galasko D (1998) CSF tau and Aβ42: logical biomarkers for Alzheimer's disease? Neurobiol Aging 19: 117-119
11. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ (1994) Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 51: 888-895
12. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopmann D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945
13. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K (2000) Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimer's Dis 2: 199-206
14. Hixon JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage by HhaI. J Lipid Res 31: 545-548
15. Hock C, Golombowski S, Muller-Spahn F, Naser W, Beyreuther K, Monning U, Schenk D, Vigo-Pelfrey C, Bush AM, Moir R, Tanzi RE, Growdon JH, Nitsch RM (1998) Cerebrospinal fluid levels of amyloid precursor protein and amyloid β-peptide in Alzheimer's disease and major depression- inverse correlation with dementia severity. Eur Neurol 39: 111-118
16. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwald H, Riemenschneider M, Deyn PD, Bancher C, Cras P, Wiltfang J, Mehta P, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of Alzheimer's disease patients from other subject groups using the combined measure of β-amyloid (1-42) and tau in CSF: a multicenter study. Neurology 52: 1555-1562
17. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, Kohno H, Imahori K (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 270: 91-94
18. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer's disease: a critical update. J Neural Transm 54: 77-95
19. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidoroko Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40 and Aβ1-42 in Alzheimer's disease: a study in Japan. Ann Neurol 44: 17-26
20. Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 54: 1875-1876
21. Klatka LA, Schiffer RB, Powers JM, Kazee AM (1996) Incorrect diagnosis of Alzheimer's disease: a clinicopathologic study. Arch Neurol 53: 35-42
22. Kosunen O, Soininen H, Paljärvi L, Heinonen O, Talasniemi S, Riekkinen SPJ (1996) Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol 91: 185-193
23. Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, Muller U, Guder W (1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer's disease. Alz Dis Assoc Disord 12: 372-377
24. McKhann G, Folstein M, Katzmann R, Price D, Stadlan EM (1984) Clinical Diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944
25. Mc Keith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines fort he clinical and pathological diagnosis of dementia with lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 47: 1113-1124
26. Mehta PD, Pirttila T, Mehta S, Serensen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57: 100-105
27. Mendez M, Mastri AR, Sung JH, Frey WH (1992) Clinically diagnosed Alzheimer's disease: neuropathologic findings in 650 cases. Alzheimer Dis Assoc Disord 6: 35-43
28. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF (2001) Cerebrospinal fluid Aβ42, tau and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 125: 510-512
29. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D (1995) Reduction of β-amyloid peptide 1-42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648
30. Munroe WA, Southwick PC, Chang L, Scharre DW, Echols CL, Fu PC, Whaley JM, Wolfert RL (1995) Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 25: 207-217
31. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedmann M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6): 1546-1554
32. Nitsch RM, Rebeck W, Deng M, Richardson UI, Tennis M, Schenk DB, Pelfrey C, Lieberburg I, Wurtmann RJ, Hytman BT (1995) Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 37: 512-518
33. Riemenschneider M, Schmolke M, Lautenschlager N, Guder W, Vanderstichele H, Vanmechelen E, Kurz A (2000) Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease. Association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 284: 85-88
34. Riemenschneider M, Schmolke M, Lautenschlager N, Vanderstichele H, Vanmechelen E, Guder W, Kurz A (2002) Association of CSF apolipoprotein E, Aβ42 and cognition in Alzheimer's disease. Neurobiol Aging 23: 205-211
35. Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, Förstl H, Kurz A (2002) Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration. Neurology 58: 1622-1628
36. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Maseu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O'Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennet DA, Fisher M, Pgata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, De Carli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-260
37. Schönknecht P, Pantel J, Werle E, Hartmann T, Essig M, Baudendistel K, Beyreuther K, Schroder J (2000) Tau-Protein-Spiegel in der Diagnostik der Alzheimer-Demenz. Fortschr Neurol Psychiatr 68: 439-446
38. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Okamoto K, Hirai S (1998) Combination assay of CSF Tau, Aβ1-40 and Aβ1-42 as a biochemical marker of Alzheimer's disease. J Neurol Sci 158: 134-140
39. Shoji M, Matsubara E, Murakami T, Manabe Y, Abe K, Kanai M, Ikeda M, Tomidokoro Y, Shizuka M, Watanabe M, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Nishimura T, Nakamura Y, Takeda M, Urakami K, Adachi Y, Nakashima K, Arai H, Sasaki H, Kanemaru K, Yamanouchi H, Yoshida Y, Ichise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Yoshida H, Toji H, Nakamura S, Hirai S (2002) Cerebrospinal fluid tau in dementia disorders: a large multicenter study by a Japanese study group. Neurobiol Aging 23: 363-370
40. Sjögren M, Minthon L, Davidsson P, Granerus AK, Clarberg A, Vanderstichele H et al (2000) CSF levels of tau, β-amyloid 42 and GAP 43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 105: 563-579
41. Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K. (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70: 624-630
42. Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, Hirai S, Furiya Y, Endoh R, Mori H (1997) Amyloid β protein 42 (43) in cerebrospinal fluid of patients with Alzheimer disease. J Neurol Sci 148: 41-45
43. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging 19: 109-116
44. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstraten P (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 38: 359-364
45. Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, coria F, Chang L, Miller B, Lieberburg I (1995) Elevation of micrtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 45: 788-793